filmov
tv
Dr. Mesa on the Utility of Ruxolitinib Versus Fedratinib in Myelofibrosis
Показать описание
Ruben Mesa, MD, the director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses the use of ruxolitinib (Jakafi) versus fedratinib (Inrebic) in patients with myelofibrosis and baseline thrombocytopenia.
0:01:00
0:01:11
0:01:06
0:01:08
0:01:12
0:01:24
0:00:45
0:00:16
0:00:15
0:00:16
0:29:57
0:00:58
0:04:11
0:00:40
0:00:36
0:00:22
0:00:21
0:22:40
0:13:10
0:02:01
0:03:26
0:00:14
0:00:15
0:08:25